- •Contents
- •Foreword
- •Preface
- •List of Abbreviations
- •1. General Topics in Ophthalmology
- •Approach to the Patient: Exam and History
- •Embryology and Development
- •Emergencies
- •Epidemiology/Statistics
- •Genetics
- •Imaging: Computed Tomography (CT)
- •Imaging: Magnetic Resonance Imaging (MRI)
- •Optics
- •Pathology
- •Pregnancy
- •Radiation/Laser
- •Surgery
- •2. Orbit, Eyelids, and Ocular Adnexa
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Infectious Disease
- •Neoplastic, Eyelid: Benign Cystic Lesions
- •Neoplastic, Eyelid: Benign Growths
- •Neoplastic, Eyelid: Hair Follicle Tumors (‘‘Tricky’’ Tumors)
- •Neoplastic, Eyelid: Premalignant Lesions
- •Neoplastic, Eyelid: Malignant Lesions
- •Neoplastic, Eyelid and Orbital: Pigmented Lesions
- •Neoplastic, Orbital: Lacrimal Gland Tumors
- •Neoplastic, Orbital: Lymphoproliferative Lesions
- •Neoplastic, Orbital: Mesenchymal Tumors
- •Neoplastic, Orbital: Metastatic and Invasive Tumors
- •Neoplastic, Orbital: Neurogenic Tumors
- •Neoplastic, Orbital: Structural Lesions
- •Neoplastic, Orbital: Vascular Lesions
- •Metabolic and Degenerative Disease
- •Systemic and Vascular Disease
- •Physical Disease
- •Inflammatory and Immune Disease
- •Eyelid Surgery
- •Lacrimal Surgery
- •Orbital Surgery
- •Other Surgery
- •3. Cornea and Conjunctiva
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Infectious Disease
- •Neoplastic Disease: Benign Masses
- •Neoplastic: Malignant
- •Neoplastic: Melanocytic Lesions
- •Metabolic and Degenerative Disease
- •Physical Disease
- •Inflammatory and Immune Disease
- •Surgery
- •4. Glaucoma
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Infantile and Pediatric Glaucoma
- •Primary Open-Angle Glaucoma
- •Secondary Open-Angle Glaucomas
- •Primary Angle-Closure Glaucoma
- •Secondary Angle-Closure Glaucoma
- •Surgery
- •Iris
- •Uveitis
- •Signs and Symptoms and Clinical Presentations of Uveitis
- •Anterior Uveitis Diagnosis and Work-Up
- •Anterior Uveitis Diseases
- •Intermediate Uveitis Diagnosis and Work-Up
- •Intermediate Uveitis Diseases
- •Posterior Uveitis Diagnosis and Work-Up
- •Posterior Uveitis Diseases
- •Panuveitis/Diffuse Uveitis
- •Surgery
- •6. Lens
- •Anatomy and Physiology
- •Signs and Symptoms
- •Congenital and Genetic Disease
- •Metabolic and Degenerative Disease
- •Systemic and Vascular Disease
- •Physical Disease
- •Cataract Surgery
- •Refractive Lens Surgery
- •7. Retina and Vitreous
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Hereditary Macular Disorders
- •Progressive Tapetoretinal Disorders
- •Stationary Tapetoretinal Disorders
- •Congenital and Genetic Vitreoretinopathies
- •Infectious Disease
- •Infectious Endophthalmitis
- •Neoplastic Disease
- •Metabolic and Degenerative Disease
- •Systemic and Vascular Disease
- •Physical Disease
- •Surgery: Laser
- •Surgery: Operative
- •8. Neurologic
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Infectious Disease
- •Neoplastic Disease
- •Metabolic and Degenerative Disease
- •Systemic and Vascular Disease
- •Physical Disease
- •Inflammatory and Immune Disease
- •Selected Cranial Nerve Abnormalities
- •Gaze Abnormalities
- •Nystagmus
- •Psychiatric Diseases
- •9. Pediatrics and Strabismus
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Congenital Disease: Phakomatoses
- •Strabismus: Esotropia
- •Strabismus: Exotropia
- •Strabismus: Vertical Deviations
- •Surgery
- •Other
- •10. Medications
- •General
- •Antibacterials: Aminoglycosides
- •Antibacterials: Cephalosporins and Penicillins
- •Antibacterials: Fluoroquinolones
- •Antibacterials: Inhibitors of Cell Wall Function
- •Antibacterials: Inhibitors of Nucleic Acid Synthesis
- •Antibacterials: Inhibitors of Protein Synthesis
- •Antibacterials: Combinations
- •Antibacterial and Corticosteroid Combinations
- •Antifungal Agents
- •Anti-inflammatory: Allergy
- •Anti-inflammatory: Nonsteroidals
- •Antiseptics
- •Antiviral Agents
- •Glaucoma: Beta-Blockers
- •Glaucoma: Carbonic Anhydrase Inhibitors
- •Glaucoma: Hyperosmotics
- •Glaucoma: Miotics/Cholinergic, Direct Acting
- •Glaucoma: Miotics/Cholinergic, Indirect Irreversible
- •Glaucoma: Prostaglandin Analogues
- •Glaucoma: Sympathomimetics
- •Immunosuppressives: Antimetabolites
- •Immunosuppressives: Alkylating Agents
- •Immunosuppressives: Noncytotoxic
- •Miotics: Cholinergic, Indirect Reversible
- •Mydriatics and Cycloplegics: Anticholinergic
- •Mydriatics: Adrenergic
- •Neurologic Medications
- •Other Agents
- •Index
RADIATION/LASER 23
TABLE 1–8
Tissue Effects of Lasers (Mnemonic: ABCD)
Action |
Chromophore |
Mechanism |
Example |
Uses |
|
|
|
|
|
Ablative and |
Nucleic acid and |
Bond-breaking |
Excimer ArF |
Refractive |
sublimation |
protein |
|
(193 nm) |
surgery |
Coagulation |
Uveal and RPE |
Thermal |
Argon green |
Retinal laser |
|
melanin |
|
(514 nm), dye |
|
Disruption |
Plasma |
Acoustomechanical |
YAG |
Capsulotomy, |
|
|
|
(1064 nm) |
LPI |
|
|
|
|
|
PREGNANCY MAY INCREASE THE RISK OF, EXACERBATE, OR PRECIPITATE
Cortical blindness; idiopathic central serous retinopathy (ICSR); ischemic optic neuropathy (ION); toxemia of pregnancy with potential serous choroidal or retinal detachments (frequently bilateral); progression of diabetic retinopathy (DR) (5% risk of proliferative diabetic retinopathy in patients with moderate nonproliferative disease); Graves’ disease; pituitary adenoma; and meningioma.
Radiation/Laser
LASER PRINCIPLES Amplification of narrow wavelength (monochromatic) light, emitting intense and coherent (synchronous with respect to time and space) radiation. Power time ¼ energy. See Table 1–8 for tissue effects of lasers.
Chromophores: substances that absorb laser energy; in the retina mainly RPE melanin, but also xanthophyll (intraretinal, peak with blue light), hemoglobin (peak with yellow light), lipofuscin, and visual pigments.
Parameters for retinal treatments
Exposure time: 0.1 seconds for most treatments. A shorter time increases the blast effect with increased risk of tissue rupture, hemorrhage, and increased temperature. A longer time increases the ‘‘cooking’’ of tissue and increases overflow with less defined burn.
Power: start low and increase.
Size: for panretinal photocoagulation (PRP) and to close tears, use 250–500 mm or larger spot (must increase power if the size increases to maintain the same energy density); use smaller 50– 100 mm in macula to limit scotoma size.
Argon and krypton lasers are generated from a high voltage passed across gas-filled tubes and emit continuously.
Blue (488 nm): not used often, as it is absorbed by xanthophylls in the macula.
Goodman, Ophtho Notes © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
24 GENERAL TOPICS IN OPHTHALMOLOGY
TABLE 1–9
The Electromagnetic Spectrum
Shorter wavelengths
Gamma rays 10 14 m, x-rays 10 10 m, ultraviolet 10 6 m, UVA 150–200 nm Visual spectrum
Violet 400 nm, blue 450–500 nm, green 500–550 nm, yellow 600 nm, red 650 nm Ophthalmic lasers
Excimer 193 nm, argon green 514 nm, HeNe 633 nm, diode 800 nm, YAG 1064 nm Longer wavelengths
Radar 10 2 m, FM radio, TV, shortwave radio 102 m, AM radio 104 m
Green (514 nm): superficial RPE; good for most conditions, highly absorbed by hemoglobin; may cause more direct closure of choroidal neovascular membrane (CNVM) vessels.
Krypton red (647 nm): deeper RPE; choriocapillaris; hurts more; use red or diode to treat through hemorrhage or nuclear sclerotic cataract; low scatter.
Dye yellow (577 nm): minimal xanthophyll absorption; low scatter, high hemoglobin absorption; useful in vascular lesions.
Diode (800 nm): solid-state continuous-wave laser (do not need a large cooling bath as with argon lasers); portable and highly efficient. Treats deeper RPE and choriocapillaris (can always see the lesion; hurts more, spares inner retina more).
ULTRAVIOLET RADIATION (MNEMONIC: ABC):
Ultraviolet A (UVA); longest wavelength; ages skin, blocked by lens
Ultraviolet B (UVB); 150–200 nm; burns skin and responsible for most skin cancer
Ultraviolet C (UVC); < 150 nm; most powerful and carcinogenic, but largely blocked by ozone
ELECTROMAGNETIC SPECTRUM See Table 1–9.
Surgery
PREOPERATIVE EVALUATION Overall perioperative mortality of eye surgery is 0.06 to 0.18%.
Anticoagulants: for most surgeries, except topical clear-corneal cataract surgery, have patient stop aspirin 7 to 10 days prior, stop other nonsteriodal anti-inflammatory drugs (NSAIDs) 1 or 2 days prior, and stop warfarin (Coumadin) 3 to 5 days before surgery.
Goodman, Ophtho Notes © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
SURGERY 25
Patients at high risk for thromboembolic disease (prosthetic heart valves, prior embolic stroke, recent deep venous thrombosis, or pulomary embolus) may need to discontinue warfarin and be hospitalized for 24 to 48 hours prior to surgery for heparin, which can then be stopped 4 to 6 hours prior to surgery. For emergent surgery, reverse warfarin with 2 to 4 units fresh frozen plasma or vitamin K 10 mg intramuscularly (IM) or subcutaneous (SQ ) every 12 hours.
One month after deep venous thrombosis (DVT) there is a 1%
risk of a DVT-related event without warfarin. The risk decreases even further with time; thus, can usually stop anticoagulation 3 months after a DVT for outpatient surgery unless the patient is hospitalized or otherwise immoblized.
Cardiac disease: accounts for half of postoperative complications; avoid elective surgery within 6 months of a myocardial infarction. In general, patients are okay to proceed with elective surgery without further testing if they have mild and stable angina, have had a heart attack more than 6 months prior, have stable congestive heart failure (CHF) and can climb one flight of stairs without stopping. Otherwise refer for patient evaluation and clearance.
Cerebrovascular disease: avoid elective surgery within 3 months of a transient ischemic attack or stroke.
Chronic obstructive pulmonary disease (COPD): aggressive preoperative treatment to prevent coughing; patient may not be able to lie flat for surgery.
Diabetes: ask about prior history of ketoacidosis; oral hypoglycemics should be stopped the morning of surgery; insulin patients should receive 1/2 dose before surgery and be maintained on intravenous fluids containing glucose until they are taking orals.
Hepatic disease: avoid elective surgery until 1 month after liver function tests have normalized.
Hypertension: in general, avoid surgery if blood pressure is > 200/ 110 mmHg; patients may take their usual antihypertensive dose on the morning of surgery.
Platelets: transfuse for < 30,000; each unit adds 10,000.
Renal failure: dialyze the day before surgery to optimize fluid and electrolyte balance and to eliminate anticoagulants used in dialysis; beware of associated qualitative platelet defects (assess with bleeding time; greater risk with blood urea nitrogen [BUN] > 60).
Steroids: patients taking more than 7.5 mg of prednisone 3 months or 40 mg of prednisone 1 week are at risk for adrenal suppression and may need a ‘‘stress’’ steroid dose (for most ophthalmic surgeries, 25 mg hydrocortisone on the day of surgery is sufficient).
Valvular heart disease: clean ophthalmologic procedures pose little risk for endocarditis; thus, no antibiotic prophylaxis is typically necessary.
Goodman, Ophtho Notes © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
.reserved rights All |
Ophtho Goodman, |
26 |
terms to subject Usage |
Thieme 2003 © Notes |
|
.license of conditions and |
|
|
TABLE 1–10
Comparison of Suture Materials
Type Material Tensile Strength Tissue Reactivity Knot Security Absorption
Absorbable (< 60 days tensile strength)
Plain gut |
Beef or sheep intestine |
7–10 days |
High |
Poor |
60–90 days |
Chromic gut |
Beef or sheep intestine |
10–20 days |
High, but less than plain gut |
Poor |
90 days |
Fast-absorbing gut |
Beef or sheep intestine |
5–7 days |
High |
Poor |
2–4 weeks |
Dexon |
Polyglycolic acid |
30 days |
Low, braided |
Good |
90 days |
Vicryl |
Polyglactin 910 |
32 days |
Low, tightly braided |
Good |
70 days |
PDS |
Polydioxanone |
28 days |
Low, stiff monofilament |
Poor |
180 days |
Maxon |
Polytrimethylene carbonate |
High |
Low |
Good |
210 days |
Monocryl |
Polyglecaprone |
High |
Low |
Good |
120 days |
Nonabsorbable (> 60 days tensile strength) |
|
|
|
|
|
Silk |
Silk (silkworm) |
1 year (variable) |
High |
Good |
2 years |
|
|
|
|
|
(variable) |
Nylon |
Polyamide |
6 months to 2 years |
Low, monofilament, braided |
Poor–fair |
15–20%/year |
Prolene |
Polypropylene |
High, indefinite |
Low, monofilament, smooth |
Poor |
Indefinite |
Polydek, Mersilene |
Polyester |
High, indefinite |
Low, braided synthetic |
Good |
Indefinite |
Novafil |
Polybutester |
High |
Low |
Good |
Indefinite |
|
|
|
|
|
|
SURGERY 27
PRINCIPLES OF SURGERY Understand that surgery is iatrogenic trauma and that most eye tissues can only repair themselves and not regenerate.
Determine goal; have a clear knowledge of surgery purpose.
Develop a well-defined plan.
Be adaptable and flexible.
Maintain good visualization of surgical field.
Minimize trauma.
Restore tissues to normal states.
Practice economy and control.
Continue with development and improvement.
SUTURE MATERIALS See Table 1–10.
Goodman, Ophtho Notes © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
